|
Email:
|
simon.salanci@upjs.sk | |
|
Homepage:
|
https://www.upjs.sk/LF/zamestnanec/simon.salanci | |
|
Fakulta:
|
LF UPJŠ
-
Univerzita Pavla Jozefa Šafárika v Košiciach, Lekárska fakulta
|
|
|
Pracovisko:
|
ULCHBKB
-
Ústav lekárskej a klinickej biochémie UPJŠ LF
|
|
|
Miestnosť:
|
||
|
Telefón:
|
||
|
ORCID iD:
|
https://orcid.org/0009-0005-6909-6164 |
|
Profilové predmety
|
|
Lekárska biochémia I., I.+II. stupeň štúdia
|
|
Vybrané publikácie
|
|
V3: Salanci, Š.; Vilková, M.; Martinez, L.; Mirossay, L.; Michalková, R.; Mojžiš, J. The Induction of G2/M Phase Cell Cycle Arrest and Apoptosis by the Chalcone Derivative 1C in Sensitive and Resistant Ovarian Cancer Cells Is Associated with ROS Generation. Int. J. Mol. Sci. 2024, 25, 7541, Q1, IF 5,7. https://doi.org/10.3390/ijms25147541 |
|
V3: Sokoli, L., Takáč, P., Budovská, M., Michalková, R., Kello, M., Nosálová, N., Balážová, Ľ., Salanci, Š., & Mojžiš, J. (2025). The Proapoptotic Effect of MB-653 Is Associated with the Modulation of Metastasis and Invasiveness-Related Signalling Pathways in Human Colorectal Cancer Cells. Biomolecules, 15(1), 72, Q1, IF 5,6. https://doi.org/10.3390/biom15010072 |
|
V3: Huniadi, M., Salanci, S., Sykora, J., Kurhajec, S. & Sarissky, M. (2022). Optimisation of flow cytometric detection of intracellular SLAMF receptor-associated adaptor proteins SAP and EAT-2. European Pharmaceutical Journal, 69(s1), 2022. 87-89. https://doi.org/10.2478/afpuc-2022-0007 |
|
V2: Salanci Š., Vilková M., Martinez L., Mirossay L., Michalková R., Mojžiš J. – Chalcone 1C as a mediator of ROS-associated cell death in ovarian cancer – 72nd Czech-Slovak Pharmacological Days Abstract Book – 2025 – s. 66 – ISBN: 978-80-574-0420-0. |
|
V2: Salanci Š., Huniadi M., Kľoc D., Sýkora J., Šarišský M. – Detection of circulating myeloma cells by NGF cytometry – Jarná škola doktorandov 2023, 9th edition: zborník príspevkov – 2023 – s. 111–117 – ISBN: 978-80-574-0212-1. |
|
Vybrané projekty
|
|
VEGA1/0617/22 - SLAMF receptory u chronickej lymfocytovej leukémie - potenciálne ciele protinádorovej liečby. - PharmDr. Marek Šarišský, PhD |
